Australian Biotech EnGeneIC Strikes Landmark Deal with Major US Biotech ImmunityBio for COVID-19 Vaccine and Cancer Treatment
Retrieved on:
Tuesday, November 30, 2021
Patient, Pancreatic cancer, Los Angeles, Cancer, McDiarmid, Technology, EDV, Temperature, Weeping Angel, IIA, Protein-bound paclitaxel, Clinical trial, Therapy, COVID-19, Phase II, Sirna, GLOBE, Globe, Antibody, III, FDA, Asbjørn Engen, Infection, Lists of countries and territories, Immune system, Immunotherapy, NEW, Toxicity, COVID, Brahmbhatt, Pharmaceutical industry, Vaccine
SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both a COVID-19 vaccine and cancer treatment.
Key Points:
- SYDNEY, Australia and NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Australian company EnGeneIC has announced a landmark deal with major US biotech ImmunityBio, over a ground-breaking approach to both a COVID-19 vaccine and cancer treatment.
- Phase I and IIa trials in patients with advanced pancreatic cancer is underway, and the FDA recently approved another trial in the US.
- ImmunityBios Executive Chairman is billionaire businessman, doctor and scientist, Patrick Soon-Shiong, who invented the drug Abraxane, used in the treatment of pancreatic cancer.
- Under the deal, EnGeneIC will grant ImmunityBio an exclusive, worldwide licence to develop, manufacture and commercialize EDV in combination with its anti-cancer drugs and COVID-19 vaccine.